Progress on basic research and clinical application of hyperthermia combined with immune checkpoint inhibitors
10.3760/cma.j.cn113030-20201207-00590
- VernacularTitle:热疗联合免疫检查点抑制剂的基础研究和临床应用进展
- Author:
Pengyuan LIU
1
;
Yajun WU
;
Zhibing WU
Author Information
1. 浙江中医药大学第二临床医学院，杭州 310053
- Keywords:
Hyperthermia;
Immune checkpoint inhibitors;
Immune sensitization
- From:
Chinese Journal of Radiation Oncology
2022;31(5):483-487
- CountryChina
- Language:Chinese
-
Abstract:
Malignant tumor is a persistent disease that perplexes public health. Traditional treatment appears ineffective for patients with advanced metastasis. In recent years, immune checkpoint inhibitor therapy has developed rapidly and has great potential, but the overall clinical efficiency is still low. Carcinoma changes the tumor microenvironment through various mechanisms, resulting in immune resistance, which greatly reduces the efficacy of immune checkpoint inhibitors. Hyperthermia can not only play the anti-tumor advantage of thermal effect, but also play a direct and indirect immune sensitization effect through a variety of ways, transforming" cold tumor" into" hot tumor" , to enhance the impact of immune checkpoint inhibitors in many patterns. Numerous basic experiments have proved that hyperthermia combined with immune checkpoint inhibitors has achieved a classy impression in mice. Presently, some ongoing clinical trials of hyperthermia combined with immune checkpoint inhibitors have gained promising progress. In this paper, the merits of combination therapy were analyzed from three aspects: immune checkpoint inhibitors, hyperthermia, hyperthermia combined with immune checkpoint inhibitors, and the future research directions of hyperthermia combined with immune checkpoint inhibitors were prospected.
